

# CURRICULUM VITAE

## PERSONAL INFORMATION

**Family name:** Józwiak  
**First name:** Katarzyna  
**Place of birth:** Poznań, Poland  
**Nationality:** Polish  
**Gender:** Female

## CONTACT INFORMATION

**Address:** Institute of Biostatistics and Registry Research  
Brandenburg Medical School Theodor Fontane  
Fehrbelliner Straße 38, 16816 Neuruppin, Germany  
**E-mail:** [Katarzyna.Jozwiak@mhb-fontane.de](mailto:Katarzyna.Jozwiak@mhb-fontane.de)  
**Phone:** +49 3391 39 14584  
**ORCID:** <https://orcid.org/0000-0002-9614-6586>

## WORK EXPERIENCE

### July 2019 - present: Statistician

Institute of Biostatistics and Registry Research  
Brandenburg Medical School Theodor Fontane, Neuruppin, Germany

### November 2013 - June 2019: Statistician

Department of Epidemiology and Biostatistics  
The Netherlands Cancer Institute, Amsterdam, The Netherlands

- February 2014 - June 2019: full time job
- November 2013 - February 2014: part time job, 0.6fte

### January 2013 - February 2014: Developer ICT

Faculty of Social and Behavioural Sciences  
Utrecht University, The Netherlands

- November 2013 - February 2014: part time job, 0.4fte
- January 2013 - October 2013: full time job

## EDUCATION

**2013: PhD** in Applied Statistics at Faculty of Social and Behavioural Sciences, Utrecht University, The Netherlands

SUPERVISORS: dr. Mirjam Moerbeek, prof. dr. Peter van der Heijden

THESIS: *Improving statistical power in studies on event occurrence by using an optimal design*

The project was funded by a VIDI grant from the Netherlands Organization for Scientific Research (NWO)

**2009: Master of Science** in Informatics and Econometrics at Faculty of Mathematics, Computer Science and Econometrics, University of Zielona Góra, Poland

SUPERVISOR: prof. dr hab. ing. Jolanta Misiewicz

THESIS:  *$\alpha$ -stable distributions for financial time series*

**2008: Master of Science** in Applied Mathematics at Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, The Netherlands

SUPERVISORS: dr. Dorota Kurowica, prof. dr. Roger M. Cooke

THESIS: *Updating parameters of the chicken processing line model*

## PROFESSIONAL MEMBERSHIP

**October 2022 - present:** Member of The Animal Experimentation Commission, State office for occupational safety, consumer protection and health, Brandenburg, Germany

## TEACHING EXPERIENCE

- 2019-2023:** Teaching during a three/four day course *Biometry* at Brandenburg Medical School Theodor Fontane in Brandenburg an der Havel, Germany; October 2019, December 2020, November 2021, November 2022, May 2023
- 2020:** Teaching during a course *In-depth research methods* at Brandenburg Medical School Theodor Fontane in Neuruppin, Germany; October-November 2020
- 2020:** Teaching during a course *Statistics I* at Brandenburg Medical School Theodor Fontane in Neuruppin, Germany; April-July 2020
- 2019:** Teaching during a course *Statistics II* at Brandenburg Medical School Theodor Fontane in Neuruppin, Germany; October 2019-January 2020
- 2013-2019:** Teaching during a five day course *Basic medical statistics for clinical and experimental research* at The Netherlands Cancer Institute, Amsterdam, The Netherlands; November 2013, December 2014, November 2015, November 2016, November 2017, November 2018, December 2019
- 2017-2018:** Teaching a workshop *Dealing with missing data* at The Netherlands Cancer Institute, Amsterdam, The Netherlands; May 2017, February 2018
- 2017:** Teaching a workshop *Sample size and power calculations for inequality tests* at The Netherlands Cancer Institute, Amsterdam, The Netherlands; February 2017
- 2013:** Assisting during a one day course *Discrete-Time Survival Analysis* at Utrecht University, The Netherlands; April 2013
- 2012:** Teaching a course *Methods and Statistics II (multivariate statistics)* during the Summer School at University College in Utrecht, The Netherlands; June-July 2012
- 2010:** Assisting during a course *Methods and Statistics II (multivariate statistics)* at University College in Utrecht, The Netherlands; September-December 2010

## INVITED AND CONTRIBUTED TALKS/PRESENTATIONS

- 2023:** "Risk prediction of the coronary heart disease in survivors of Hodgkin Lymphoma." Invited oral presentation at *Risk Prediction, Communication and Perception (RiPCoP) in Health*, Neuruppin, Germany, June 2023
- 2012:** "PODSE: a computer Program for Optimal designs of trials with Discrete-time Survival Endpoints." Oral presentation at *V European Congress of Methodology*, Santiago de Compostela, Spain, July 2012
- 2011:** "Optimal Treatment Allocation and Study Duration for Trials with Discrete-Time Survival Endpoints." Poster presentation at *Designed Experiments: Recent Advances in Methods and Applications, DEMA Workshop*, Cambridge, The United Kingdom, September 2011
- 2011:** "Optimal Randomization for Trials with Discrete-Time Survival Endpoints." Invited oral presentation at *Academy Colloquium Cost Efficient and Optimal Designs for Social and Biomedical Sciences*, Amsterdam, The Netherlands, April 2011
- 2010:** "Cost-Effective Designs for Trials with Discrete-Time Survival Endpoints." Invited oral presentation at *IV European Congress of Methodology jointly with 27th Biennial Conference of the Society for Multivariate Analysis in the Behavioral Sciences, EAM-SMABS*, Potsdam, Germany, July 2010

## COMPUTER SKILLS

Programming in SPSS, STATA, R and Matlab  
Text editing in LaTeX, Word

## LANGUAGES

Polish - mother language  
English - proficient  
German - intermediate

## PUBLICATIONS

1. Sollfrank L, Linn SC, Hauptmann M, **Jóźwiak K**. A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer. *BMC Med Res Methodol*, 2023; 23: 154
2. Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, zu Eulenburg C, Kates R, **Jóźwiak K**, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HRD/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HRD/HER2L trial. *Ann Oncol*, 2023; 34 (6): 531-542
3. Henneman R, Rouwenhorst L, Karakullukcu MB, Smeele LE, Lohuis PFJM, van den Brekel MWM, Hamming-Vrieze O, **Jóźwiak K**, Balm AJM. Surgical site complications of isolated salvage neck dissection post (chemo-) radiation – a cohort analysis (1997 – 2017). *Eur J Surg Oncol*, 2023; 49 (4): 764-770
4. Harbeck N, Nitz UA, Matthias C, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Augustin D, Scheffen I, Malter W, von Schumann R, Just M, zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, **Jóźwiak K**, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O. De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial. *J Clin Oncol*. In press
5. de Vries S, Haaksma ML, **Jóźwiak K**, Schaapveld M, Hodgson DC, Lugtenburg PJ, Krol ADG, Petersen EJ, van Spronsen DJ, Ahmed S, Hauptmann M, Aleman BMP, van Leeuwen FE. Development and validation of a risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma. *J Clin Oncol*, 2023; 41 (1): 86-95
6. Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke E-M, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, **Jóźwiak K**, zu Eulenburg C, Kreipe HH, Harbeck N. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. *Clin Cancer Res*, 2022; 28 (22): 4995-5003
7. Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Acosta AT, Grijpink-Ongering LG, Gonzalez M, **Jóźwiak K**, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. *Nat Med*, 2022; 28: 1178-1188

8. de Jong VMT, Wang Y, ter Hoeve ND, Opdam M, Stathonikos N, **Józwiak K**, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Cordoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC. Prognostic value of stromal tumor infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. *J Clin Oncol*, 2022; 40: 2361-2374
9. de Boo LW, **Józwiak K**, Joensuu H, Lindman H, Lanttia S, Opdam M, van Steenis C, Brugman W, Kluin RJC, Schouten PC, Kok M, Nederlof PM, Hauptmann M, Linn SC. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. *Br J Cancer*, 2022; 126 (10): 1401-1409
10. Nachtigall I, Bonsignore M, Thürmann P, Hohenstein S, **Józwiak K**, Hauptmann M, Eifert S, Dengler J, Bollmann A, Groesdonk HV, Kuhlen R, Meier-Hellmann A. Sex differences in clinical course and intensive care unit admission in a national cohort of hospitalized patients with COVID-19. *J Clin Med*, 2021; 10 (21): 4954
11. van der Willik KD, **Józwiak K**, Hauptmann M, van de Velde EED, Compter A, Ruiter R, Stricker BH, Ikram MA, Schagen SB. Change in cognition before and after non-central nervous system cancer diagnosis: A population-based cohort study. *Psycho-Oncol*, 2021; 30(10): 1699-1710
12. Dackus GMHE, **Józwiak K**, Sonke GS, van der Wall E, van Diest PJ, Siesling S, Hauptmann M, Linn SC. Adjuvant aromatase inhibitors or tamoxifen following chemotherapy for perimenopausal breast cancer patients. *J Natl Cancer Inst*, 2021; 113 (11): 1506-1514
13. Dideczneit-Sandhop B, **Józwiak K**, Jolie M, Holdys J, Hauptmann M. Hearing loss among elderly people and access to hearing aids: a cross-sectional study from a rural area in Germany. *Eur Arch Oto-Rhino-L*, 2021; 278 (12): 5093-5098
14. Greaser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, **Józwiak K**, Christgen M, Kuemmel S, Grischke E-M, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. *J Immunother Cancer*, 2021; 9(5): e002198
15. van Seijen M, **Józwiak K**, Pinder SE, Hall A, Krishnamurthy S, Thomas JSJ, Collins LC, Bijron J, Bart J, Cohen D, Ng W, Bouybayoune I, Stobart H, Hudecek J, Schaapveld M, Thompson A, Lips EH, Wesseling J. Variability in grading of ductal carcinoma in situ among an international group of pathologists. *J Pathol Clin Res*, 2021; 7: 233-242
16. Geenen JJJ, Dackus GMHE, Schouten PC, Pluim D, Marchetti S, Sonke GS, **Józwiak K**, Huitema ADR, Beijnen JH, Schnellens JHM, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. *Int J Cancer*, 2021; 148: 3041-3050
17. Dackus GMHE, **Józwiak K**, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Sonke GS, Linn SC. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. *Breast Cancer Res Treat*, 2021; 185: 817-830
18. Boekhout AH, Rogiers A, **Józwiak K**, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Rozeman EA, Neyns B, Janssen KJ, van de Poll-Franse LV, Blank CU. Health-related quality of life of long-term advanced melanoma survivors treated with Anti-CTLA-4 immune checkpoint inhibition compared to matched controls. *Acta Oncol*, 2021; 60(1): 69-77

19. Nachtigall I, Lenga P, **Jóźwiak K**, Thürmann P, Meier-Hellmann A, Kuhlen R, Brederlau J, Bauer T, Tebbenjohanns J, Schwegmann K, Hauptmann M, Dengler J. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. *Clin Microbiol Infect*, 2020; 26: 1663-1669
20. Verheij FS, Bakkers C, van Eden WJ, Aalbers AGJ, Nienhuijs SW, **Jóźwiak K**, de Hingh IHJT, Kok NFM. Comparison of the Peritoneal Cancer Index and Dutch region count as tools to stage patients with peritoneal metastases of colorectal cancer. *BJS Open*, 2020; 4 (6): 1153-1161
21. van der Willik KD, Yilmaz P, Compter A, Hauptmann M, **Jóźwiak K**, Ruiter R, Stricker BHCh, Vernooij MW, Ikram MA, de Ruiter MB, Schagen SB. Brain structure prior to non-central nervous system cancer diagnosis: a population-based cohort study. *NeuroImage Clin*, 2020; 28: 102466
22. Retèl VP, Byng D, Linn SC, **Jóźwiak K**, Koffijberg H, Rutgers EJ, Cardoso F, Piccart M, Poncet C, van 't Veer LJ, van Harten WH. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomized controlled trial. *Eur J Cancer*, 2020; 137: 193-203
23. Zavrakidis J, **Jóźwiak K**, Hauptmann M. Statistical analysis of longitudinal data on tumour growth in mice experiments. *Scientific Reports*, 2020; 10: 9143
24. Blok JM, Pluim I, Daugaard G, Wagner T, **Jóźwiak K**, Wilthagen EA, Looijenga LHJ, Meijer RP, Bosch JLHR, Horenblas S. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: A systematic review and meta-analysis. *BJU Int*, 2020; 125: 355-368
25. Henneman R, Berger DMS, Karakullukcu MB, Smeele LE, Lohuis PFJM, **Jóźwiak K**, van der Hage JA, Balm AJM. Surgical site complications after parotid gland surgery for benign tumors in a centralized setting: A Clavien-Dindo class cohort analysis. *Eur J Surg Oncol*, 2020; 46 (2): 258-262
26. Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, **Jóźwiak K**, van den Belt-Dusebout AW, Gietema JA, Schaapveld M. Platinum exposure and cause-specific mortality among patients with testicular cancer. *Cancer*, 2020; 126(3): 628-639
27. van der Willik KD, Hauptmann M, **Jóźwiak K**, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram MA, Schagen SB. Trajectories of cognitive function prior to cancer diagnosis: A population-based study. *J Natl Cancer Inst*, 2020; 112 (5): 480-488.
28. Madu MF, Franke V, van de Wiel BA, Klop WMC, **Jóźwiak K**, van Houdt WJ, Wouters MWJM, van Akkooi ACJ. External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: Who needs adjuvant treatment? *Melanoma Res*, 2020; 30(2): 185-192
29. Baltussen EJM, Brouwer de Koning SG, Hendriks BHW, **Jóźwiak K**, Sterenberg HJCM, Ruers TJM. Comparing in vivo and ex vivo fiberoptic diffuse reflectance spectroscopy in colorectal cancer. *Transl Biophotonics*, 2019; 1: e201900008
30. de Boer LL, Kho E, **Jóźwiak K**, van de Vijver KK, Vranken Peeters M-JTFD, van Duijnhoven F, Hendriks BHW, Sterenberg HJCM, Ruers TJM. Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens. *J Biomed Opt*, 2019; 24(11): 115004
31. Kho E, de Boer LL, Post AL, van de Vijver KK, **Jóźwiak K**, Sterenberg HJCM, Ruers TJM. Imaging depth variations in hyperspectral imaging: development of a method to detect tumor up to the required tumor-free margin width. *J Biophotonics*, 2019; 12(11): e201900086

32. Min LA, Vogel WV, Lahaye MJ, Maas M, Donswijk M, Vegt E, Kusters M, Zijlmans HJ, **Jóźwiak K**, Roberti S, Beets-Tan RGH, Lambregts DMJ. Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies – effect on staging outcomes and diagnostic confidence. *Eur Radiol*, 2019; 29: 6900-6910
33. Puppe J, Opdam M, Schouten PC, **Jóźwiak K**, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretic L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Buttner R, Mallmann P, Schomig-Markiefka B, Schmutzler R, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. *Clin Cancer Res*, 2019; 25: 4351-62
34. Elbers JBW, Veldhuis LI, Bhairosing PA, Smeele LE, **Jóźwiak K**, van den Brekel MWM, Verheij M, Al-Mamgani A, Zuur CL. Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation. *Eur Arch Otorhinolaryngol*, 2019; 276: 647-655
35. Berger DMS, Wassenberg RM, **Jóźwiak K**, van de Wiel BA, Balm AJM, van den Berg JG, Klop WMC. Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system. *Eur J Surg Oncol*, 2019; 45(2): 235-241
36. Elbers JBW, Al-Mamgani A, van den Brekel MWM, **Jóźwiak K**, de Boer JP, Lohuis PJFM, Willems SM, Verheij M, Zuur CL. Salvage surgery for recurrence after radiotherapy for squamous cell carcinoma of the head and neck. *Otolaryngol Head Neck Surg*, 2019; 160(6): 1023-1033
37. van Eden WJ, Kok NFM, Snaebjornsson P, **Jóźwiak K**, Woensdregt K, Bottenberg P, Boot H, Aalbers AGJ. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms. *BJS Open*, 2019; 3: 376-386
38. Madu MF, Franke V, van de Wiel BA, Klop WMC, **Jóźwiak K**, van Houdt WJ, Wouters MWJM, van Akkooi ACJ. External validation of the 8th edition melanoma staging system of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. *J Clin Oncol*, 2018; 36(15-suppl): 9500-9500
39. Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Hendricksena K, Horenblas S, **Jóźwiak K**, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A. Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma. *Scan J of Urology*, 2018; 52(5-6): 411-418
40. Krul IMK, Opstal-Van Winden AWJ, Janus CPM, Daniels LA, Appelman Y, Maas AHM, de Vries S, **Jóźwiak K**, Aleman BMP, van Leeuwen F. Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma. *J Am Coll Cardiol*, 2018; 72(25): 3374-3375
41. Kuusk T, Donswijk ML, Valdes Olmos RA, De Bruijn RE, Brouwer OR, Hendricksen K, Horenblas S, **Jóźwiak K**, Prevoo W, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A. An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors. *EJNMMI Res*, 2018; 8: 105
42. Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes AJ, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, **Jóźwiak K**, Horenblas S, van Leeuwen FE, Schaapveld M. Risk of diabetes after para-aortic radiation for testicular cancer. *Br J Cancer*, 2018; 119: 901-907

43. Ottenhof SR, Djajadiningrat RS, Thygesen HH, Jakobs PJ, **Jóźwiak K**, Heeren AM, de Jong J, Sanders J, Horenblas S, Jordanova ES. The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma. *Front Immunol*, 2018; 9: 1253
44. Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klumpen H, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Incrocci L, van den Bergh ACM, **Jóźwiak K**, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M. Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era. *J Clin Oncol*, 2018; 36(4): 2504-2513
45. Brouwer de Koning SG, Vranken Peeters MTFD, **Jóźwiak K**, Bhairosing P, Ruers TJM. Tumor resection margin definitions in breast-conserving surgery: Systematic review and meta-analysis of the current literature. *Clin Breast Cancer*, 2018; 18(4): e595-e600
46. Volders JH, Negenborn VL, Haloua MH, Krekel NMA, **Jóźwiak K**, Meijer S, van den Tol MP. Breast-specific factors determine cosmetic outcome and patient satisfaction after breast-conserving therapy: Results from the randomized COBALT study. *J Surg Oncol*, 2018; 117: 1001-1008
47. de Vries S, Schaapveld M, van Nimwegen FA, **Jóźwiak K**, Lugtenburg PJ, Daniels LA, Roesink JM, van der Maazen RWM, Kok WEM, Aleman BMP, van Leeuwen FE. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. *Br J Cancer*, 2018; 118: 887-895
48. Dackus GM, **Jóźwiak K**, Sonke GS, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Linn SC. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. *Eur J Cancer*, 2018; 90: 92-101
49. Elbers JBW, Al-Mamgani A, Paping D, van den Brekel MWM, **Jóźwiak K**, de Boer JP, Karakullukcu B, Verheij M, Zuur CL. Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity. *Oral Oncol*, 2017; 75: 163-168
50. Dackus GMHE, ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop EA, Willems SM, van Deurzen CHM, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Voogd A, **Jóźwiak K**, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Linn SC. Long-term prognosis of young breast cancer patients ( $\leq 40$  years) who did not receive adjuvant systemic treatment: Protocol for the PARADIGM initiative cohort study. *BMJ Open*, 2017; 7(11): e017842
51. Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, **Jóźwiak K**, Klop WMC, Wouters MWJM, Akkooi ACJ, van de Wiel BA. Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumor burden criteria. *Eur J Cancer*, 2017; 87: 212-215
52. Kadouch DJ, Elshot YS, Zupan-Kajcovski B, van Haersma de With ASE, van der Wal AC, Leeflang M, **Jóźwiak K**, Wolkerstorfer A, Bekkenk MW, Spuls PI, de Rie MA. One-stop-shop with confocal microscopy imaging vs. standard of care surgical treatment of basal cell carcinoma: an open label, non-inferiority, randomized controlled multicenter trial. *Br J Dermatol*, 2017; 177: 735-741
53. Madu MF, Schopman JHH, Berger DMS, Klop WMC, **Jóźwiak K**, Wouters MWJM, van der Hage JA, van Akkooi ACJ. Clinical prognostic markers in stage IIIC melanoma. *J Surg Oncol*, 2017; 116: 244-251
54. Volders JH, Negenborn VL, Haloua MH, Krekel NMA, **Jóźwiak K**, Meijer S, van den Tol MP. Cosmetic outcome and quality of life are inextricably linked in breast conserving therapy. *J Surg Oncol*, 2017; 115: 941-948

55. Rigter LS, Spaander MCW, Moons LM, Bisseling TM, Aleman BMP, de Boer JP, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, Raemaekers JMM, van der Maazen RWM, Cats A, Bleiker EMA, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, **Jóźwiak K**, te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: Study design. *BMC Cancer*, 2017; 17(1), 112
56. Madu MF, Deken MM, van der Hage JA, **Jóźwiak K**, Wouters MWJM, van Akkooi ACJ. Isolated limb perfusion for melanoma is safe and effective in elderly patients. *Ann Surg Oncol*, 2017; 24: 1997-2005
57. Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Kolk RHE, Lopes Cardozo AMF, Bosch AM, de Widt-Levert LM, van der Veene H, Rijna H, Taets van Amerongen AHM, **Jóźwiak K**, Meijer S, van den Tol MP. Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: Final outcomes of a randomized controlled trial (COBALT). *EJSO*, 2017; 43(4): 649-657
58. van Eden WJ, Kok NFM, **Jóźwiak K**, Beets GL, van Leerdam ME, Boot H, Aalbers AGJ. Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Dis Colon Rectum*, 2017; 60(5): 477-487
59. de Boer LL, Hendriks BHW, van Duijnhoven F, Vrancken Peeters-Baas M-JTFD, van de Vijver K, Loo CE, **Jóźwiak K**, Sterenborg HJCM, Ruers TJM. Using DRS during breast conserving surgery: Identifying robust optical parameters and influence of inter-patient variation. *Biomed Opt Express*, 2016; 7 (12): 5188-5200
60. ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, **Jóźwiak K**, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. *J Natl Cancer Inst*, 2016; 108 (11)
61. Madu MF, Wouters MWJM, Klop WMC, van der Hiel B, van de Wiel BA, **Jóźwiak K**, van der Hage JA, van Akkooi ACJ. Clinical prognostic markers in stage III-B melanoma. *Ann Surg Oncol*, 2016; 23 (13): 4195-4202
62. van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk MJJ, Land JA, Goddijn M, van Golde RJT, van Rumste MM, Schats R, **Jóźwiak K**, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE. Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. *JAMA*, 2016; 316 (3): 300-312
63. Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Barbe E, Sietses C, **Jóźwiak K**, Meijer S, van den Tol MP. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study. *EJSO*, 2016; 42(7): 986-993
64. Haloua MH, Volders JH, Krekel NMA, Barbe E, Sietses C, **Jóźwiak K**, Meijer S, van den Tol MP. A nationwide pathology study on surgical margins and excision volumes after breast-conserving surgery: There is still much to be gained. *The Breast*, 2016; 25: 14-21
65. Haloua MH, Volders JH, Krekel NMA, Lopes Cardozo AMF, de Roos WK, de Widt-Levert LM, van der Veen H, Rijna H, Bergers E, **Jóźwiak K**, Meijer S, van den Tol MP. Intraoperative ultrasound guidance in breast-conserving surgery improves cosmetic outcomes and patient satisfaction: Results of a multicenter randomized controlled trial (COBALT). *Ann Surg Oncol*, 2016; 23 (1): 30-37
66. Theunissen EAR, Zuur CL, **Jóźwiak K**, Lopez-Yurda M, Hauptmann M, Rasch CRN, van der Baan S, de Boer JP, Dreschler WA, Balm AJM. Prediction of hearing loss due to cisplatin chemoradiotherapy. *JAMA Otolaryngol Head Neck Surg*, 2015; 141(9): 810-815



67. **Józwiak K**, Moerbeek M. Optimal designs for trials with discrete-time survival endpoints. *OA Epidemiology*, 2013; 1(3): 22. Invited paper.
68. Moerbeek M, **Józwiak K**. Optimal designs for event history analysis. *Zeitschrift für Psychologie*, 2013; 221(3): 160-173. Invited paper for special issue on optimal designs.
69. **Józwiak K**, Moerbeek M. PODSE: A computer Program for Optimal design of trials with Discrete-time Survival Endpoints. *Comput Methods Programs Biomed*, 2013; 111: 115-127
70. **Józwiak K**, Moerbeek M. Optimal treatment allocation and study duration for trials with discrete-time survival endpoints. *J Stat Plan Inference*, 2013; 143: 971-982
71. **Józwiak K**, Moerbeek M. Accrual by groups in trials with discrete-time survival endpoints. *Clin Trials*, 2012; 10: 32-42
72. **Józwiak K**, Moerbeek M. Cost-effective designs for trials with discrete-time survival endpoints. *Comput Stat Data Anal*, 2012; 56: 2086-2096
73. **Józwiak K**, Moerbeek M. Power analysis for trials with discrete-time survival endpoints. *J Educ Behav Stat*, 2012; 37(5): 630-654
74. Kurowicka D, Nauta M, **Józwiak K**, Cooke R. Updating parameters of the chicken processing line model. *Risk Anal*, 2010; 30(6): 934-944

#### **EDITORIALS AND LETTERS AND RESPONSES**

1. Dackus GMHE, **Józwiak K**, Hauptmann M, Linn SC. Response to Klar and Adams. *J Natl Cancer Inst*, 2022; 114 (1): 167-168